Wiping out the white space in clinical trials
Yendou reduces years of delays in clinical trials
Life Sciences Today this week
Zina Sarif, founder and CEO of Yendou, shares her journey from Morocco to Europe, where she pursued chemistry and a PhD in skin cancer research before moving into clinical operations at Parexel and AstraZeneca.
There she discovered the massive “white space” in drug development—up to four years of administrative delay between trial phases, largely driven by slow, repetitive site communication.
Yendou addresses this by acting as a sponsor–site communication platform with site‑centric data architecture and login‑free workflows for sites.
It structures all interactions, automates follow‑ups, and enables reuse of site data across studies, cutting feasibility timelines by 50%, reducing site selection by 13 weeks, and getting 91% of tasks completed within five days.
With 5,000+ sites and 62 site networks already onboard, Zina frames clinical operations as “agents of medical progress” and argues that the real moat is relentless usefulness and execution, not defensive barriers.
Watch this high-energy episode 48 - on how Zina Sarif and her team in Berlin are reducing clinical trial site selection by 13 weeks.
About me
My name is Danny Lieberman. I’m the host of Life Sciences Today.
Book a call with me if you’re innnovating at the intersection of technology and biology and you want the world to know what you’re doing!
For 25+ years I’ve worked across tech, cybersecurity, privacy, and clinical data — from Israeli MedTech startups to Verily, Amgen, and the Fortune 1 company.
Most MedTech companies run their business with 4 separate operating systems: an engineering OS, a regulatory OS, an operations OS, a commercial OS.
They don’t run their business on a single risk OS.
That’s how they get derailed and accumulate expensive mistakes like in today’s story.
If you want a clear view of what’s likely to break in your 2026 plan, book a CEO Audit.
The CEO Audit is a discrete 60’ call with me where we’ll talk about team, capital, reimbursement, regulatory, and operational risk - quietly growing up to bite you.
You’ll get a written post-call summary with action and watch items, and unlimited access to my Pattern Library.